Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from BeOne Medicines Ltd ( (HK:6160) ) is now available.
BeOne Medicines Ltd., a Switzerland-based oncology-focused biopharmaceutical company listed in Hong Kong, develops cancer therapies including combination regimens and potential first-in-class treatments for blood cancers such as chronic lymphocytic leukemia. The group reports financials under U.S. GAAP, underscoring its alignment with international investors and regulatory standards.
The company released unaudited consolidated results for the three months ended March 31, 2026, alongside business updates and revised full-year 2026 financial guidance. Management cautioned that the guidance is preliminary, has not been reviewed by auditors, and is subject to significant uncertainties and risks, advising shareholders and potential investors to exercise caution in dealing in its securities.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$290.00 price target. To see the full list of analyst forecasts on BeOne Medicines Ltd stock, see the HK:6160 Stock Forecast page.
More about BeOne Medicines Ltd
BeOne Medicines Ltd. is a Switzerland-incorporated biopharmaceutical company focused on oncology, developing and commercializing cancer therapies including fixed-duration combinations and next-generation targeted treatments for conditions such as chronic lymphocytic leukemia. The company is listed in Hong Kong and reports under U.S. GAAP, highlighting its cross-border capital markets presence and global growth ambitions in cancer drug development.
Average Trading Volume: 3,721,116
Technical Sentiment Signal: Buy
Current Market Cap: HK$263.1B
See more insights into 6160 stock on TipRanks’ Stock Analysis page.